JILIN AODONG(SZ:000623) Shang Hai Zheng Quan Bao·2025-10-30 22:47Core Viewpoint - The company, Jilin Aodong Pharmaceutical Group Co., Ltd., has disclosed its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information presented [1][2][10]. Financial Data - The third-quarter financial report has not been audited [3][7]. - The company does not require retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3][4]. Shareholder Information - The total number of ordinary shareholders and the situation of the top ten shareholders have been reported, but there are no changes due to securities lending activities [5][6]. Board Meeting - The 19th meeting of the 11th Board of Directors was held on October 30, 2025, with all nine directors present [8][9]. - The board approved the third-quarter report and the proposal to adjust external investments and introduce strategic investors, with unanimous support [10][12][26]. Investment Adjustment - The company plans to adjust its external investments and introduce strategic investors to optimize the capital structure of its subsidiary, Aodong Pharmaceutical (Anhui) Co., Ltd. [16][22]. - The registered capital of Aodong Anhui will be reduced from 300 million yuan to 20 million yuan, with the company terminating its planned investment of 3 million yuan [18][20]. - A new strategic investor, Zhongneng Shuzhi Technology (Shanghai) Co., Ltd., will be introduced, holding 40% of the shares [20][22]. Purpose and Impact of Adjustment - The adjustment aims to focus on core business development and enhance market competitiveness, particularly in key regions like Shanghai [22]. - The company believes this adjustment will optimize resource allocation and control investment risks, aligning with its long-term strategic interests [24].